Abstract
The ideal first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC) remains unknown pending results of randomized trials. Although mUC tumours are sensitive to chemotherapy, response durations are short. A new retrospective study provides data on the effectiveness of first-line PD-1/PD-L1 inhibitors compared with carboplatin-based chemotherapy in this setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
